Back to Careers

Juvena’s Director of Discovery & Platform, Dr. Thach Mai presents “Mapping the therapeutic potential of secreted proteins through integrating AI and quantitative multi-omics technology” at the Element Biosciences Roadshow

Back to Careers

Jeremy O’Connell presents video discussing JUV-161 for myotonic dystrophy type 1 (DM1)

Back to Careers

CEO and co-Founder Dr. Hanadie Yousef recognized as In Vivo’s 2024 Rising Leaders, which includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.

Back to Careers

One of In Vivo’s 2024 Rising Leaders, Dr. Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company’s lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.

Back to Careers

Juvena’s CMO Dr. Barney King participates in the Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.

Back to Careers

CEO Dr. Hanadie Yousef participates in a panel on “Demystifying Aging” at Horizons Ventures 2024 Techcracker summit 

Back to Careers

Juvena CEO and CO-Founder Dr. Hanadie Yousef featured in San Francisco Business Times article highlighting women biotech leaders

Back to Careers

Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1.

Back to Careers

Juvena recognized by The Wall Street Journal for developing regenerative therapies aimed at weight loss and prevention of muscle wasting